Literatur
-
1
Bjorge J D, Jakymiw A, Fujita D J.
Selected glimpses into the activation and function of Src kinase.
Oncogene.
2000;
19
5620-5635
-
2
Blume-Jensen P, Hunter T.
Oncogenic kinase signalling.
Nature.
2001;
411
355-65
-
3
Boguski M S, McCormick F.
Proteins regulating Ras and its relatives.
Nature.
1993;
366
643-654
-
4
Cantley L C.
The phosphoinositide 3-kinase pathway.
Science.
2002;
296
1655-1657
-
5
Druker B J. et al .
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Nat Med.
1996;
2
561-566
-
6
Ferrara N.
Vascular endothelial growth factor as a target for anticancer therapy.
Oncologist.
2004;
9
2-10
-
7
Gibbs J B.
Anticancer drug targets: growth factors and growth factor signaling.
J Clin Invest.
2000;
105
9-13
-
8
Hayes A J, Li L Y, Lippman M E.
Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment.
Bmj.
1999;
318
853-856
-
9
Hurwitz H. et al .
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med.
2004;
350
2335-2342
-
10
Irby R B. et al .
Activating SRC mutation in a subset of advanced human colon cancers.
Nat Genet.
1999;
21
187-190
-
11
Lewis T S, Shapiro P S, Ahn N G.
Signal transduction through MAP kinase cascades.
Adv Cancer Res.
1998;
74
49-139
-
12
Schwartz G K. et al .
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.
J Clin Oncol.
2002;
20
2157-2170
-
13
Sebti S M, Der C J.
Searching for the elusive targets of farnesyltransferase inhibitors.
Nat Rev Cancer.
2003;
3
945-951
-
14
Vigneri P, Wang J Y.
Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.
Nat Med.
2001;
7
228-234
-
15
Vivanco I, Sawyers C L.
The phosphatidylinositol 3-Kinase AKT pathway in human cancer.
Nat Rev Cancer.
2002;
2
489-501
-
16
Zhou B B, Bartek J.
Targeting the checkpoint kinases: chemosensitization versus chemoprotection.
Nat Rev Cancer.
2004;
4
216-225
-
17
Zwerner J P, May W A.
Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines.
Oncogene.
2002;
21
3847-3854
Dr. med. Christian Grimm
Abteilung Innere Medizin II, Medizinische Universitätsklinik Freiburg
Hugstetter Straße 55
79106 Freiburg
Phone: 0761/270-3401
Fax: 0761/270-3762
Email: grimm@med1.ukl.uni-freiburg.de; christian.grimm@email.de
